{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:04:56Z","timestamp":1785776696182,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Critically ill immunocompromised (CIIC) patients with pulmonary infection are a population at high risk for invasive pulmonary aspergillosis (IPA). The host defenses are important factors to consider in determining the risk and outcome of infection. Quantification of changes in the status of host immunity could be valuable for clinical diagnosis and outcome prediction.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We evaluated the quantitative changes in key humoral and cellular parameters in CIIC patients with pulmonary infection and their potential influence on the risk and prognosis of IPA. We monitored the evolution of these parameters in 150 CIIC patients with pulmonary infection on days 1, 3 and 10 (D1, D3 and D10) following ICU admission. The primary outcome was 28-day mortality. Follow-up included 60- and 90-day mortality.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Among the 150 CIIC patients included in this study, 62 (41.3%) had microbiological evidence of IPA. Compared with patients without IPA, CD3<jats:sup>+<\/jats:sup>, CD8<jats:sup>+<\/jats:sup>, CD28<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup> and CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cell counts (D1, D3 and D10) and B-cell counts (D1 and D3) were significantly reduced in patients with IPA (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Multivariate regression analysis revealed that CD8<jats:sup>+<\/jats:sup> (D3 and D10) (odds ratio (OR) 0.34, 95% confidence interval (CI) 0.23 to 0.46; OR 0.68, 95% CI 0.56 to 0.80), CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> (D3) (OR 0.73, 95% CI 0.61 to 0.86) and CD3<jats:sup>+<\/jats:sup> (D10) (OR 0.81, 95% CI 0.63 to 0.98) T-cell counts were independent predictors of IPA in CIIC patients. Receiver operating characteristic analysis of immune parameters predicting 28-day mortality revealed area under the curve values of 0.82 (95% CI 0.71 to 0.92), 0.94 (95% CI 0.87 to 0.99), and 0.94 (95% CI 0.85 to 0.99) for CD8<jats:sup>+<\/jats:sup> T-cell counts (D1, D3 and D10, respectively) and 0.84 (95% CI 0.75 to 0.94), 0.92 (95% CI 0.85 to 0.99) and 0.90 (95% CI 0.79 to 0.99) for CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cell counts (D1, D3 and D10, respectively). Kaplan-Meier survival analysis provided evidence that CD8<jats:sup>+<\/jats:sup> and CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cell counts (&lt;149.5 cells\/mm<jats:sup>3<\/jats:sup> and &lt;75 cells\/mm<jats:sup>3<\/jats:sup>, respectively) were associated with early mortality in CIIC patients with IPA (logrank test; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>CD8<jats:sup>+<\/jats:sup> and CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cell counts were significantly lower in CIIC patients with IPA than in non-IPA patients. Lower CD8<jats:sup>+<\/jats:sup> and CD28<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cell counts in CIIC patients with pulmonary infection were associated with higher risk and early mortality in IPA and may be valuable for clinical diagnosis and outcome prediction.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc12836","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T19:58:35Z","timestamp":1374695915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CD8+T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Na","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"1924_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1532\/IJH97.E0625","volume":"85","author":"C Ferr\u00e0","year":"2007","unstructured":"Ferr\u00e0 C, Marcos P, Misis M, Morgades M, Bordej\u00e9 ML, Oriol A, Lloveras N, Sancho JM, Xicoy B, Batlle M, Klamburg J, Feliu E, Ribera JM: Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. Int J Hematol. 2007, 85: 195-202. 10.1532\/IJH97.E0625.","journal-title":"Int J Hematol"},{"key":"1924_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.200309-1322SO","volume":"170","author":"RM Kotloff","year":"2004","unstructured":"Kotloff RM, Ahya VN, Crawford SW: Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004, 170: 22-48. 10.1164\/rccm.200309-1322SO.","journal-title":"Am J Respir Crit Care Med"},{"key":"1924_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","volume":"67","author":"G Maschmeyer","year":"2007","unstructured":"Maschmeyer G, Haas A, Cornely OA: Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007, 67: 1567-1601. 10.2165\/00003495-200767110-00004.","journal-title":"Drugs"},{"key":"1924_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jhin.2004.01.006","volume":"56","author":"KH Vandewoude","year":"2004","unstructured":"Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D: Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004, 56: 269-276. 10.1016\/j.jhin.2004.01.006.","journal-title":"J Hosp Infect"},{"key":"1924_CR5","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1056\/NEJMra064928","volume":"357","author":"JA Fishman","year":"2007","unstructured":"Fishman JA: Infection in solid organ transplant recipients. N Engl J Med. 2007, 357: 2601-2614. 10.1056\/NEJMra064928.","journal-title":"N Engl J Med"},{"key":"1924_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Mu\u00f1oz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group, et al: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008, 46: 1813-1821. 10.1086\/588660.","journal-title":"Clin Infect Dis"},{"key":"1924_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","unstructured":"American Thoracic Society; Infectious Diseases Society of America: Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005, 171: 388-416.","journal-title":"Am J Respir Crit Care Med"},{"key":"1924_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","volume":"20","author":"American College of Chest Physicians; Society of Critical Care Medicine Consensus Conference","year":"1992","unstructured":"American College of Chest Physicians; Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guideline for the use of innovative therapies in sepsis. Crit Care Med. 1992, 20: 864-874. 10.1097\/00003246-199206000-00025.","journal-title":"Crit Care Med"},{"key":"1924_CR9","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s00134-007-0791-z","volume":"33","author":"RJ Trof","year":"2007","unstructured":"Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB: Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007, 33: 1694-1703. 10.1007\/s00134-007-0791-z.","journal-title":"Intensive Care Med"},{"key":"1924_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097\/00003246-198510000-00009.","journal-title":"Crit Care Med"},{"key":"1924_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, Reinhart CK, Suter PM, Thijs LG, on behalf of the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. Intensive Care Med. 1996, 22: 707-710. 10.1007\/BF01709751.","journal-title":"Intensive Care Med"},{"key":"1924_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, de Mendon\u00e7a A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S, Working Group on \u201cSepsis-related Problems\u201d of the European Society of Intensive Care Medicine: Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998, 26: 1793-1800. 10.1097\/00003246-199811000-00016.","journal-title":"Crit Care Med"},{"key":"1924_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CCM.0b013e3181cb0cdc","volume":"38","author":"MM Levy","year":"2010","unstructured":"Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC, Surviving Sepsis Campaign: The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010, 38: 367-374. 10.1097\/CCM.0b013e3181cb0cdc.","journal-title":"Crit Care Med"},{"key":"1924_CR14","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1007\/s00277-003-0766-2","volume":"82","author":"D Buchheidt","year":"2003","unstructured":"Buchheidt D, B\u00f6hme A, Cornely OA, F\u00e4tkenheuer G, Fuhr HG, Heussel G, Junghanss C, Karthaus M, Kellner O, Kern WV, Schiel X, Sezer O, S\u00fcdhoff T, Szel\u00e9nyi H, Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO): Diagnosis and treatment of documented infections in neutropenic patients: recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003, 82: S127-S132. 10.1007\/s00277-003-0766-2.","journal-title":"Ann Hematol"},{"key":"1924_CR15","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011, 52: e56-e93. 10.1093\/cid\/cir073.","journal-title":"Clin Infect Dis"},{"key":"1924_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA: CDC\/NHSN surveillance definition of health care associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008, 36: 309-332. 10.1016\/j.ajic.2008.03.002.","journal-title":"Am J Infect Control"},{"key":"1924_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00134-008-1336-9","volume":"35","author":"A Torres","year":"2009","unstructured":"Torres A, Ewig S, Lode H, Carlet J, European HAP Working Group: Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med. 2009, 35: 9-29. 10.1007\/s00134-008-1336-9.","journal-title":"Intensive Care Med"},{"key":"1924_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMp038219","volume":"350","author":"A Torres","year":"2004","unstructured":"Torres A, Ewig S: Diagnosing ventilator-associated pneumonia. N Engl J Med. 2004, 350: 433-435. 10.1056\/NEJMp038219.","journal-title":"N Engl J Med"},{"key":"1924_CR19","unstructured":"Chinese State Food and Drug Administration: Good Clinical Practice (SFDA Order No. 3, 1 September 2003). [http:\/\/www.bioon.com\/drug\/chemdrug\/243155.shtml]"},{"key":"1924_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/01.CCM.0000055380.86458.1E","volume":"31","author":"CM Luna","year":"2003","unstructured":"Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C: Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003, 31: 676-682. 10.1097\/01.CCM.0000055380.86458.1E.","journal-title":"Crit Care Med"},{"key":"1924_CR21","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.2174\/138161208784980545","volume":"14","author":"K Lyn-Kew","year":"2008","unstructured":"Lyn-Kew K, Standiford TJ: Immunosuppression in sepsis. Curr Pharm Des. 2008, 14: 1870-1881. 10.2174\/138161208784980545.","journal-title":"Curr Pharm Des"},{"key":"1924_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nri2939","volume":"11","author":"L Romani","year":"2011","unstructured":"Romani L: Immunity to fungal infections. Nat Rev Immunol. 2011, 11: 275-288. 10.1038\/nri2939.","journal-title":"Nat Rev Immunol"},{"key":"1924_CR23","doi-asserted-by":"publisher","first-page":"e9036","DOI":"10.1371\/journal.pone.0009036","volume":"5","author":"N Chaudhary","year":"2010","unstructured":"Chaudhary N, Staab JF, Marr KA: Healthy human T-cell responses to Aspergillus fumigatus antigens. PLoS One. 2010, 5: e9036-10.1371\/journal.pone.0009036.","journal-title":"PLoS One"},{"key":"1924_CR24","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.4049\/jimmunol.169.10.5787","volume":"169","author":"LL Ma","year":"2002","unstructured":"Ma LL, Spurrell JC, Wang JF, Neely GG, Epelman S, Krensky AM, Mody CH: CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J Immunol. 2002, 169: 5787-5795.","journal-title":"J Immunol"},{"key":"1924_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1084\/jem.173.4.793","volume":"173","author":"GB Huffnagle","year":"1991","unstructured":"Huffnagle GB, Yates JL, Lipscomb MF: Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med. 1991, 173: 793-800. 10.1084\/jem.173.4.793.","journal-title":"J Exp Med"},{"key":"1924_CR26","doi-asserted-by":"publisher","first-page":"7920","DOI":"10.4049\/jimmunol.174.12.7920","volume":"174","author":"DM Lindell","year":"2005","unstructured":"Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB: Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J Immunol. 2005, 174: 7920-7928.","journal-title":"J Immunol"},{"key":"1924_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2249.2005.02738.x","volume":"140","author":"G Ramadan","year":"2005","unstructured":"Ramadan G, Davies B, Kurup VP, Keever-Taylor CA: Generation of cytotoxic T cell responses directed to human leucocyte antigen class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol. 2005, 140: 81-91. 10.1111\/j.1365-2249.2005.02738.x.","journal-title":"Clin Exp Immunol"},{"key":"1924_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMp068087","volume":"355","author":"AH Sharpe","year":"2006","unstructured":"Sharpe AH, Abbas AK: T-cell costimulation: biology, therapeutic potential, and challenges. N Engl J Med. 2006, 355: 973-975. 10.1056\/NEJMp068087.","journal-title":"N Engl J Med"},{"key":"1924_CR29","doi-asserted-by":"publisher","first-page":"R26","DOI":"10.1186\/cc7731","volume":"13","author":"J Monserrat","year":"2009","unstructured":"Monserrat J, de Pablo R, Reyes E, D\u00edaz D, Barcenilla H, Zapata MR, De la Hera A, Prieto A, Alvarez-Mon M: Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care. 2009, 13: R26-10.1186\/cc7731.","journal-title":"Crit Care"},{"key":"1924_CR30","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.4049\/jimmunol.163.5.2358","volume":"163","author":"KA Newell","year":"1999","unstructured":"Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, Zhou P, Hart J, Thistlethwaite JR, Bluestone JA: Cutting edge: blockade of the CD28\/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999, 163: 2358-2362.","journal-title":"J Immunol"},{"key":"1924_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 2011, 331: 44-49. 10.1126\/science.1198687.","journal-title":"Science"},{"key":"1924_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/infdis\/jiq062","volume":"203","author":"S Schmidt","year":"2011","unstructured":"Schmidt S, Tramsen L, Hanisch M, Latg\u00e9 JP, Huenecke S, Koehl U, Lehrnbecher T: Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J Infect Dis. 2011, 203: 430-435. 10.1093\/infdis\/jiq062.","journal-title":"J Infect Dis"},{"key":"1924_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S1369-5274(02)00337-5","volume":"5","author":"A Casadevall","year":"2002","unstructured":"Casadevall A, Feldmesser M, Pirofski L: Induced humoral immunity and vaccination against major human fungal pathogens. Curr Opin Microbiol. 2002, 5: 386-391. 10.1016\/S1369-5274(02)00337-5.","journal-title":"Curr Opin Microbiol"},{"key":"1924_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056\/NEJM200103083441001.","journal-title":"N Engl J Med"},{"key":"1924_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jama.288.7.862","volume":"288","author":"D Annane","year":"2002","unstructured":"Annane D, S\u00e9bille V, Charpentier C, Bollaert PE, Fran\u00e7ois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troch\u00e9 G, Chaumet-Riffaud P, Bellissant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002, 288: 862-871. 10.1001\/jama.288.7.862.","journal-title":"JAMA"},{"key":"1924_CR36","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJMoa010307","volume":"345","author":"E Rivers","year":"2001","unstructured":"Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001, 345: 1368-1377. 10.1056\/NEJMoa010307.","journal-title":"N Engl J Med"},{"key":"1924_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1399-3062.2010.00499.x","volume":"12","author":"SY Park","year":"2010","unstructured":"Park SY, Kim SH, Choi SH, Sung H, Kim MN, Woo JH, Kim YS, Park SK, Lee JH, Lee KH, Lee SG, Han DJ, Lee SO: Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis. 2010, 12: 309-315. 10.1111\/j.1399-3062.2010.00499.x.","journal-title":"Transpl Infect Dis"},{"key":"1924_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1128\/IAI.73.1.494-503.2005","volume":"73","author":"V Balloy","year":"2005","unstructured":"Balloy V, Huerre M, Latg\u00e9 JP, Chignard M: Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun. 2005, 73: 494-503. 10.1128\/IAI.73.1.494-503.2005.","journal-title":"Infect Immun"},{"key":"1924_CR39","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc4823","volume":"10","author":"KH Vandewoude","year":"2006","unstructured":"Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D: Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care. 2006, 10: R31-10.1186\/cc4823.","journal-title":"Crit Care"},{"key":"1924_CR40","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccm.2011.06.001","volume":"32","author":"DE Craven","year":"2011","unstructured":"Craven DE, Hudcova J, Lei Y: Diagnosis of ventilator-associated respiratory infections (VARI): microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP). Clin Chest Med. 2011, 32: 547-557. 10.1016\/j.ccm.2011.06.001.","journal-title":"Clin Chest Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12836.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc12836\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12836.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:04:01Z","timestamp":1728306241000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc12836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,8]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1186\/cc12836","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,24]]},"assertion":[{"value":"8 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R157"}}